CLOVIS ONCOLOGY INC (CLVS) Stock Analyst Earnings Estimates
NASDAQ:CLVS - Nasdaq - US1894641000 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 143M 49.90% | 164.5M 15.03% | 148.757M -9.57% | 131.8M -11.40% | 158.8M 20.49% | 172.03M 8.33% | 183.24M 6.52% | 187.99M 2.59% | |
| EBITDA YoY % growth | -359.53M -9.21% | -293.9M 18.25% | -211.795M 27.94% | -186.66M 11.87% | -106.08M 43.17% | -34.68M 67.31% | -73.736M -112.62% | -110.958M -50.48% | |
| EBIT YoY % growth | -367.3M -10.04% | -302.1M 17.75% | -220.291M 27.08% | -199.327M 9.52% | -142.434M 28.54% | -97.439M 31.59% | -133.425M -36.93% | -174.813M -31.02% | |
| Operating Margin | -256.85% | -183.65% | -148.09% | -151.23% | -89.69% | -56.64% | -72.81% | -92.99% | |
| EPS YoY % growth | -7.49 -5.94% | -4.34 42.06% | -2.29 47.24% | -1.64 28.29% | -0.80 51.24% | -0.48 40.13% | -0.68 -42.83% | -1.00 -45.68% |
All data in USD
| Q4 / 22 | |
|---|---|
| EPS Q2Q % growth | -0.32 34.13% |
| Revenue Q2Q % growth | 32.17M -10.56% |
| EBITDA Q2Q % growth | -38.76M 12.34% |
| EBIT Q2Q % growth | -41.557M 21.16% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2022 Q2Q % growth | -0.39 30.36% | -0.42 | 0.03 | 7.49% |
| Q2 2022 Q2Q % growth | -0.50 18.03% | -0.42 | -0.08 | -18.60% |
| Q1 2022 Q2Q % growth | -0.44 31.25% | -0.44 | 0.00 | 0.26% |
| Q4 2021 Q2Q % growth | -0.48 52.94% | -0.58 | 0.10 | 17.44% |
| Q3 2021 Q2Q % growth | -0.56 37.08% | -0.49 | -0.07 | -14.86% |
| Q2 2021 Q2Q % growth | -0.61 46.96% | -0.58 | -0.03 | -5.85% |
| Q1 2021 Q2Q % growth | -0.64 50.00% | -0.73 | 0.09 | 12.65% |
| Q4 2020 Q2Q % growth | -1.02 43.65% | -0.79 | -0.23 | -29.87% |
| Q3 2020 Q2Q % growth | -0.89 50.00% | -1.01 | 0.12 | 12.01% |
| Q2 2020 Q2Q % growth | -1.15 49.34% | -1.07 | -0.08 | -7.95% |
| Q1 2020 Q2Q % growth | -1.28 21.47% | -1.30 | 0.02 | 1.88% |
| Q4 2019 Q2Q % growth | -1.81 | -1.74 | -0.07 | -3.95% |
| Q3 2019 Q2Q % growth | -1.78 | -1.93 | 0.15 | 7.72% |
| Q2 2019 Q2Q % growth | -2.27 | -1.75 | -0.52 | -29.84% |
| Q1 2019 Q2Q % growth | -1.63 | -1.77 | 0.14 | 8.16% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2022 Q2Q % growth | 30.663M -19.13% | 33.885M | -3.222M | -9.51% |
| Q2 2022 Q2Q % growth | 32.143M -12.70% | 37.771M | -5.628M | -14.90% |
| Q1 2022 Q2Q % growth | 34.247M -9.99% | 37.715M | -3.468M | -9.20% |
| Q4 2021 Q2Q % growth | 35.968M -16.93% | 38.406M | -2.438M | -6.35% |
| Q3 2021 Q2Q % growth | 37.916M -2.20% | 40.238M | -2.322M | -5.77% |
| Q2 2021 Q2Q % growth | 36.82M -7.70% | 42.164M | -5.344M | -12.67% |
| Q1 2021 Q2Q % growth | 38.05M -10.60% | 45.437M | -7.387M | -16.26% |
| Q4 2020 Q2Q % growth | 43.3M 10.15% | 44.081M | -781K | -1.77% |
| Q3 2020 Q2Q % growth | 38.77M 3.11% | 43.494M | -4.724M | -10.86% |
| Q2 2020 Q2Q % growth | 39.89M 20.95% | 45.541M | -5.651M | -12.41% |
| Q1 2020 Q2Q % growth | 42.56M 28.50% | 42.067M | 493K | 1.17% |
| Q4 2019 Q2Q % growth | 39.31M | 39.749M | -439K | -1.10% |
| Q3 2019 Q2Q % growth | 37.6M | 36.555M | 1.045M | 2.86% |
| Q2 2019 Q2Q % growth | 32.98M | 35.62M | -2.64M | -7.41% |
| Q1 2019 Q2Q % growth | 33.12M | 32.882M | 238K | 0.72% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | N/A | 9.3% | N/A |
| Revenue | 0% | N/A | -3.44% | N/A |